Is Interleukin-6 blockade a viable strategy to prevent progression of acute respiratory distress syndrome in non-COVID viral pneumonia?
作者信息
Padappayil Rana Prathap, Yarrarapu Siva Naga S, Tiperneni Raghu, Li Boning
机构信息
Internal Medicine, Monmouth Medical Center, United States.
Pulmonary and Critical Care Medicine, Monmouth Medical Center, United States.
出版信息
Clin Immunol Commun. 2023 Dec;3:21-22. doi: 10.1016/j.clicom.2023.02.004. Epub 2023 Feb 10.
Abstract
摘要
相似文献
1
Is Interleukin-6 blockade a viable strategy to prevent progression of acute respiratory distress syndrome in non-COVID viral pneumonia?阻断白细胞介素-6是否是预防非新冠病毒肺炎患者急性呼吸窘迫综合征进展的可行策略？
Clin Immunol Commun. 2023 Dec;3:21-22. doi: 10.1016/j.clicom.2023.02.004. Epub 2023 Feb 10.
2
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.一项评估静脉注射瑞维鲁单抗对比 COVID-19 重症肺炎、急性肺损伤或急性呼吸窘迫综合征患者最佳支持治疗的疗效和安全性的 III 期开放性标签、随机对照研究：一项随机对照试验研究方案的结构性总结。
Trials. 2020 Jul 13;21(1):639. doi: 10.1186/s13063-020-04548-z.
3
Specific Viral Etiologies Are Associated With Outcomes in Pediatric Acute Respiratory Distress Syndrome.特定病毒病因与儿科急性呼吸窘迫综合征的结局相关。
Pediatr Crit Care Med. 2019 Sep;20(9):e441-e446. doi: 10.1097/PCC.0000000000002008.
4
Comparison of the Clinical Course of COVID-19 Pneumonia and Acute Respiratory Distress Syndrome in 2 Passengers from the Cruise Ship Diamond Princess in February 2020.2020年2月钻石公主号邮轮上两名乘客的新型冠状病毒肺炎与急性呼吸窘迫综合征临床病程比较
Am J Case Rep. 2020 Aug 19;21:e926835. doi: 10.12659/AJCR.926835.
5
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.抗白细胞介素药物治疗重症 COVID-19 患者（COV-AID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.
6
Coronavirus Disease 2019 ICU Patients Have Higher-Than-Expected Acute Physiology and Chronic Health Evaluation-Adjusted Mortality and Length of Stay Than Viral Pneumonia ICU Patients.COVID-19 重症监护病房患者的急性生理学与慢性健康状况评估调整死亡率和住院时间高于病毒性肺炎重症监护病房患者。
Crit Care Med. 2021 Jul 1;49(7):e701-e706. doi: 10.1097/CCM.0000000000005012.
7
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?我们能否使用白细胞介素 6（IL-6）阻断剂治疗 2019 冠状病毒病（COVID-19）引起的细胞因子释放综合征（CRS）？
J Autoimmun. 2020 Jul;111:102452. doi: 10.1016/j.jaut.2020.102452. Epub 2020 Apr 10.
8
COVID-19 related acute respiratory distress syndrome: Pathological, radiological and clinical concordance.COVID-19 相关的急性呼吸窘迫综合征：病理、影像学和临床的一致性。
Tuberk Toraks. 2021 Sep;69(3):360-368. doi: 10.5578/tt.20219708.
9
COVID-19 versus Non-COVID-19 Acute Respiratory Distress Syndrome: Comparison of Demographics, Physiologic Parameters, Inflammatory Biomarkers, and Clinical Outcomes.COVID-19 与非 COVID-19 急性呼吸窘迫综合征：人口统计学、生理参数、炎症生物标志物和临床结局比较。
Ann Am Thorac Soc. 2021 Jul;18(7):1202-1210. doi: 10.1513/AnnalsATS.202008-1026OC.
10
Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial.COVID-19 肺炎无急性低氧性呼吸衰竭患者早期使用地塞米松治疗的效果及急性呼吸窘迫综合征的发生风险（EARLY-DEX COVID-19）：一项随机对照试验的研究方案。
Trials. 2022 Sep 15;23(1):784. doi: 10.1186/s13063-022-06722-x.
引用本文的文献
1
The Role of Inflammation in the Pathogenesis of Viral Respiratory Infections.炎症在病毒性呼吸道感染发病机制中的作用
Microorganisms. 2024 Dec 7;12(12):2526. doi: 10.3390/microorganisms12122526.
本文引用的文献
1
Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials.托珠单抗治疗 COVID-19 肺炎住院患者：随机对照试验的系统评价和荟萃分析。
J Investig Med. 2022 Jan;70(1):55-60. doi: 10.1136/jim-2021-002001. Epub 2021 Sep 24.
2
Dynamically linking influenza virus infection kinetics, lung injury, inflammation, and disease severity.动态关联流感病毒感染动力学、肺损伤、炎症和疾病严重程度。
Elife. 2021 Jul 20;10:e68864. doi: 10.7554/eLife.68864.
3
Interleukin-6 blocking agents for treating COVID-19: a living systematic review.白细胞介素 6 阻断剂治疗 COVID-19：一项实时系统评价。
Cochrane Database Syst Rev. 2021 Mar 18;3(3):CD013881. doi: 10.1002/14651858.CD013881.
4
Cytokine Storm.细胞因子风暴
N Engl J Med. 2020 Dec 3;383(23):2255-2273. doi: 10.1056/NEJMra2026131.
5
Influenza Virus-Induced Robust Expression of SOCS3 Contributes to Excessive Production of IL-6.流感病毒诱导 SOCS3 的强烈表达有助于过度产生 IL-6。
Front Immunol. 2019 Aug 16;10:1843. doi: 10.3389/fimmu.2019.01843. eCollection 2019.
6
The Role of Interleukin 6 During Viral Infections.白细胞介素6在病毒感染中的作用。
Front Microbiol. 2019 May 10;10:1057. doi: 10.3389/fmicb.2019.01057. eCollection 2019.
7
Pathogenesis of influenza-induced acute respiratory distress syndrome.流感导致的急性呼吸窘迫综合征的发病机制。
Lancet Infect Dis. 2014 Jan;14(1):57-69. doi: 10.1016/S1473-3099(13)70286-X. Epub 2013 Nov 13.
8
IL-1 β and IL-6 upregulation in children with H1N1 influenza virus infection.甲型 H1N1 流感病毒感染患儿白细胞介素-1β和白细胞介素-6 的上调。
Mediators Inflamm. 2013;2013:495848. doi: 10.1155/2013/495848. Epub 2013 Apr 29.
9
Clinical characteristics of influenza virus infection in juvenile idiopathic arthritis patients treated with tocilizumab.托珠单抗治疗幼年特发性关节炎患者流感病毒感染的临床特征。
Mod Rheumatol. 2013 Sep;23(5):972-6. doi: 10.1007/s10165-012-0780-0. Epub 2012 Oct 16.
10
Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection.白细胞介素-6是严重甲型H1N1流感大流行感染的潜在生物标志物。
PLoS One. 2012;7(6):e38214. doi: 10.1371/journal.pone.0038214. Epub 2012 Jun 5.
Zotero 插件